Anoushka Menon
Anoushka Menon is a British-Indian geneticist and entrepreneur whose career has been shaped by a personal reckoning with the gaps in women's reproductive healthcare. She studied genetics at the University of Cambridge before going on to work in the diagnostics and women's health space, first at Thriva Health — where she launched the company's women's health products — and subsequently at The Lowdown, a women's health information platform. These roles gave her a close-up view of the structural underinvestment in female-specific diagnostics and the clinical blindspots that shaped her founding decision.
Menon met her co-founder Dr Andreas Hadjimitsis through the Entrepreneur First accelerator in May 2024. Their shared personal experiences with reproductive health conditions, including PCOS, and their complementary skills — her background in genetics and growth, his in computational and wet-lab diagnostics — led them to focus on the uterine environment, one of the most underexplored components of fertility medicine. Their company, Genie Fertility, launched from stealth in October 2025 with $1.22 million in pre-seed funding.
As CEO of Genie Fertility, Menon leads the development of what the company describes as the world's first non-invasive diagnostic for uterine health, using menstrual blood — the monthly shedding of the entire uterine lining — as a source of molecular biomarkers. The company's machine learning platform, trained on data from over 200,000 fertility patients, identifies novel markers of uterine health that can be improved through existing clinical interventions. Clinical studies began in March 2025, with IVF groups across the UK and Europe and medical advisors from Imperial College London and Harvard Medical School collaborating on the programme.
Menon has spoken publicly about the need to bring the same diagnostic rigour to uterine health that has been applied to sperm, egg, and embryo assessment in fertility treatment. Genie Fertility's vision extends beyond fertility into diagnostics and therapeutics for PCOS, endometriosis, and perimenopause, conditions that collectively affect hundreds of millions of women and have been historically neglected in medical research.
